Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. The Journal of clinical investigation. 2024. 134. 7
Yoshihiko Fujita, Hiromichi Matsuoka, Yasutaka Chiba, Junji Tsurutani, Takeshi Yoshida, Kiyohiro Sakai, Miki Nakura, Ryo Sakamoto, Chihiro Makimura, Yoichi Ohtake, et al. Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain. Oncology letters. 2023. 26. 2. 355-355
Hiromichi Matsuoka, Junji Tsurutani, Yasutaka Chiba, Yoshihiko Fujita, Kiyohiro Sakai, Takeshi Yoshida, Miki Nakura, Ryo Sakamoto, Chihiro Makimura, Yoichi Ohtake, et al. Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study). The Oncologist. 2022
Satoru Hagiwara, Takeshi Yoshida, Naoshi Nishida, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Masahiro Takita, Tomoko Aoki, Masahiro Morita, Hirokazu Cishina, et al. Progression from early to advanced stage of immune-related cholangitis. Hepatology research : the official journal of the Japan Society of Hepatology. 2022. 52. 10. 888-892
Hiroaki Akamatsu, Shunsuke Teraoka, Hidetoshi Hayashi, Daichi Fujimoto, Atsushi Hayata, Koji Haratani, Yuichi Ozawa, Takeshi Yoshida, Tsutomu Iwasa, Toshio Shimokawa, et al. Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study. JTO clinical and research reports. 2021. 2. 7. 100184-100184